Table 3.

 MR estimates of BMI (SD, 1 SD = 4.5 kg/m²) on cardiovascular risk factors and CHD

Exposure: BMI (n = 322,154)	Effect estimate	95% CI	p value
CHD (n = 60,801 case and 123,504 control participants)a
IVW	1.45	1.27, 1.66	< 0.001
Weighted-median	1.44	1.24, 1.67	< 0.001
MR-Egger regression
Slope	1.55	1.26, 1.91	< 0.001
Intercept (directional pleiotropy)	1.00	0.99, 1.00	0.50
Type 2 diabetes mellitus (n = 34,840 case and 114,981 control participants)a
IVW	1.96	1.35, 2.83	< 0.001
Weighted-median	2.63	2.16, 3.21	< 0.001
MR-Egger regression
Slope	3.42	2.63, 4.46	< 0.001
Intercept (directional pleiotropy)	0.98	0.98, 0.99	< 0.001
Fasting glucose, mmol/l (n = 46,186)b
IVW	0.07	0.03, 0.11	< 0.001
Weighted-median	0.08	0.05, 0.12	< 0.001
MR-Egger regression
Slope	0.09	0.036, 0.15	< 0.001
Intercept	−0.0007	−0.002, 0.001	0.37
HbA1c, % (n = 46,368)b
IVW	0.05	0.01, 0.08	0.005
Weighted-median	0.09	0.04, 0.14	< 0.001
MR-Egger regression
Slope	0.09	0.008, 0.16	0.03
Intercept	−0.001	−0.003, 0.001	0.31
Fasting insulin, log-pmol/l (n = 38,238)b
IVW	0.18	0.14, 0.22	< 0.001
Weighted-median	0.18	0.12, 0.24	< 0.001
MR-Egger regression
Slope	0.16	0.07, 0.25	< 0.001
Intercept	0.0007	−0.002, 0.003	0.60
LDL-cholesterol, SD (1 SD = 1.0 mmol/l) (n = 188,577)b
IVW	−0.05	−0.19, 0.09	0.50
Weighted-median	−0.01	−0.08, 0.05	0.66
MR-Egger regression
Slope	−0.10	−0.184, − 0.02	0.02
Intercept	0.0016	−0.001, 0.004	0.19
HDL-cholesterol, SD (1 SD = 0.40 mmol/l) (n = 188,577)b
IVW	−0.23	−0.32, −0.15	< 0.001
Weighted-median	−0.21	−0.27, −0.16	< 0.001
MR-Egger regression
Slope	−0.23	−0.307, −0.15	< 0.001
Intercept	−0.0001	−0.002, 0.002	0.90
Triacylglycerol, SD (1 SD = 1.024 mmol/l) (n = 188,577)b
IVW	0.20	0.14, 0.26	< 0.001
Weighted-median	0.21	0.15, 0.27	< 0.001
MR-Egger regression
Slope	0.17	0.09, 0.24	< 0.001
Intercept	0.001	−0.001, 0.003	0.37

^aBinary outcome—effect estimate is the OR for a 1 SD increase in BMI

^bContinuously measured outcome—effect estimate is the difference in mean in the unit provided in column 1 for a 1 SD increase in BMI